ScanGlean
Take the Fit Check Fit Check

Blog

GLP-1 Drugs for Longevity: What the Evidence Actually Shows (2026)

ScanGlean Editorial Team · September 19, 2026 · 27 min read

Walk into a growing number of concierge longevity clinics in 2026, and alongside the DEXA scan and the bloodwork panel, you’ll find a menu item that has nothing to do with diabetes or obesity: a GLP-1 prescription, dosed at a quarter or a third of what the FDA approved it for, sold to people who are already a normal weight, under the banner of “metabolic longevity” or “healthy aging.”

This is one of the strangest gaps in preventive health content anywhere online right now. On one side, there is genuinely elite, hard-won clinical trial evidence — a 17,604-person cardiovascular outcomes trial, a kidney-disease trial big enough to stop early for efficacy, real-world data on more than a million patients — showing these drugs do things far beyond lowering blood sugar. On the other side, that same evidence gets stretched, in clinic marketing and social media, to cover a use — low-dose, indefinite, in healthy non-obese people, for the explicit purpose of slowing aging — that has never been tested in a single randomized trial. Almost nothing written for a general audience holds those two facts in the same paragraph.

This article does. The short version: the trial evidence for cardiovascular and kidney outcomes in people with obesity, diabetes, or existing disease is some of the most rigorous in modern medicine. The leap to “microdosing for longevity” in healthy people is, as of 2026, a hypothesis being marketed as a conclusion.

Key takeaways

  • The 2023 SELECT trial (17,604 people, average 40 months of follow-up) found semaglutide cut cardiovascular death, heart attack, or stroke by 20% in people with overweight/obesity and existing cardiovascular disease — even without diabetes. This is genuinely strong evidence, and it’s the foundation everything else in this space is built on.
  • “GLP-1 microdosing for longevity” — 25-50% of the standard dose, indefinitely, in lean and metabolically healthy people — has no FDA-approved indication and no published randomized trial evidence as of 2026. A prospective study is underway; results aren’t in yet.
  • Roughly 25-40% of the weight lost on these drugs is lean muscle mass, not fat — a meaningfully worse ratio than diet-only weight loss, and a real concern for anyone using these drugs long-term for reasons other than treating obesity.
  • Stopping the drug undoes most of its benefit fast: trial participants regained roughly two-thirds (semaglutide) to more than half (tirzepatide) of their lost weight within a year of discontinuation, along with the metabolic improvements that came with it.
  • The FDA’s most alarming recent safety signal — suicidal ideation — was formally walked back in January 2026 after a review of nearly 108,000 trial participants found no increased risk. A separate boxed warning for thyroid tumors, based on rodent data, remains and has not been confirmed in human studies of common thyroid cancers.
  • Nobody has data on 20-40 years of continuous use, which is the actual time horizon “longevity dosing” implies. Every safety conclusion in this article rests on trials that ran one to five years.

Quick Answer: Does the Evidence Support Your Situation?

Your situation What the evidence actually supports
Overweight/obese with type 2 diabetes, existing heart disease, or chronic kidney disease Strong, randomized-trial-level evidence for meaningful cardiovascular and kidney benefit — this is the population the landmark trials were run in
Overweight/obese, otherwise healthy, considering it mainly for weight loss Strong evidence for weight loss and improved cardiometabolic markers; be aware of the lean-mass and rebound-weight issues covered below
Normal weight, healthy, considering “microdosing” for anti-aging or longevity No randomized trial evidence exists for this specific use; you would be an early adopter of an unproven off-label protocol, not a beneficiary of the trials clinics cite
Considering a compounded (non-brand) version to save money The legal and safety picture has shifted sharply against compounded GLP-1s since both branded-drug shortages resolved in late 2024/early 2025 — see the safety section below before choosing this route
Worried specifically about the suicidal-ideation warnings you may have heard about The FDA’s own 2026 review of ~108,000 trial participants found no increased risk and requested the warning’s removal — this specific concern has largely been resolved by the evidence
Concerned about muscle loss while on the drug A real, well-documented effect — resistance training and higher protein intake are the only mitigation strategies with study support so far

Not sure whether a GLP-1 program — or any other preventive intervention — actually fits your situation? Answer a few quick, non-identifying questions and get personalized eligibility guidance across all 6 categories ScanGlean covers. Take the Fit Check →

What Are GLP-1 Drugs, and Why Did Longevity Clinics Start Selling Them?

GLP-1 receptor agonists mimic a hormone your gut naturally releases after eating, which signals your pancreas to release insulin, slows stomach emptying, and acts on appetite centers in the brain. Semaglutide (sold as Ozempic for diabetes, Wegovy for obesity) and tirzepatide (a dual GLP-1/GIP agonist, sold as Mounjaro for diabetes and Zepbound for obesity) are the two dominant drugs in this class as of 2026.

They were approved first for type 2 diabetes, then for obesity, on the strength of trials showing dramatic weight loss — commonly 15-21% of body weight over roughly 68-72 weeks in the pivotal obesity trials. That alone would have made them a major public health story. What pulled them into the longevity conversation specifically was a second wave of trials asking a different question: do these drugs help people who don’t have diabetes, independent of how much weight they lose?

The Real Evidence: Two Trials That Changed the Conversation

SELECT: cardiovascular protection without diabetes. Published in the New England Journal of Medicine in December 2023, the SELECT trial (led by researcher A. Michael Lincoff and colleagues) randomized 17,604 adults with overweight or obesity and pre-existing cardiovascular disease — but explicitly without diabetes — to weekly semaglutide 2.4mg or placebo. Over a mean follow-up of 39.8 months, semaglutide reduced the composite outcome of cardiovascular death, non-fatal heart attack, or non-fatal stroke by 20%. This was the first large trial to show a GLP-1 drug protecting the heart in people who weren’t diabetic, and it’s the single strongest piece of evidence behind the “these drugs do more than treat blood sugar” argument that longevity clinics lean on.

FLOW: slowing kidney disease. Published in NEJM in 2024, the FLOW trial (led by researcher Vlado Perkovic and colleagues) randomized 3,533 people with type 2 diabetes and chronic kidney disease to semaglutide or placebo. The trial was stopped early because the benefit was clear enough that continuing would have been unethical to the placebo group: semaglutide reduced the composite of kidney failure, a sustained large drop in kidney function, or kidney-related death by 21% (hazard ratio 0.79), while also cutting major cardiovascular events by 18%.

Together, these two trials are why “GLP-1 drugs are a legitimate longevity intervention, not just a weight-loss drug” is a defensible sentence — for the populations actually studied. That caveat matters more than almost anything else in this article, because it’s exactly the part that gets dropped when the claim travels from a cardiology journal to a clinic’s Instagram post.

Where the Evidence Runs Out: Microdosing in Healthy People

Here is the gap almost no consumer content is honest about. “Longevity dosing” or “microdosing” — typically 25-50% of the FDA-approved maintenance dose, used indefinitely in people who are not significantly overweight, for the stated purpose of reducing inflammation or slowing aging rather than losing weight — is a genuinely different intervention from what SELECT and FLOW tested. Those trials enrolled people with obesity and, in most cases, existing cardiovascular or kidney disease, at full therapeutic doses.

AgelessRx, a longevity-focused telehealth company, explicitly markets GLP-1 microdoses as “a powerful new path to promoting long-term wellness” and is running a prospective cohort study (registered as NCT07092605 on ClinicalTrials.gov) to evaluate microdosed semaglutide’s effect on health, quality of life, and longevity measures. That a company is actively running the study to find out is itself the clearest evidence that the answer isn’t known yet. As bariatric medicine specialist Katy Williams of University of Missouri Health Care told Science News in its reporting on the trend, “there is no rigorous scientific data to support microdosing.”

There is a plausible biological rationale — GLP-1 drugs have documented anti-inflammatory and anti-oxidative effects in mechanistic studies, and observational data (discussed below) hints at benefits beyond weight loss. Plausible is not the same as proven, and the honest position in 2026 is that this specific use case — low dose, healthy person, indefinite duration, anti-aging intent — is an experiment people are running on themselves at longevity clinics, not a therapy validated by the trials those same clinics cite in their marketing.

The Alzheimer’s Story: A Trial That Failed and Data That Didn’t

This is one of the more instructive parts of the GLP-1 longevity story, because it shows both how promising and how easily oversold this drug class can be.

The trial that failed. In December 2025, Novo Nordisk presented topline results from the Phase 3 EVOKE and EVOKE+ trials — 3,808 participants with mild cognitive impairment or dementia due to Alzheimer’s disease, randomized to oral semaglutide or placebo — at the Clinical Trials on Alzheimer’s Disease conference. Semaglutide did not slow disease progression on the trials’ primary endpoints, despite improving some related biomarkers. This was a real, well-powered, randomized failure — not a case of “more research needed.”

The observational signal that persists. At the same time, a separate line of research using a very different method — target trial emulation on real-world electronic health record data — has repeatedly found an association between semaglutide use and lower future risk of an Alzheimer’s diagnosis in people with type 2 diabetes. Researcher William Wang and colleagues, using a database covering 116 million U.S. patients, emulated seven target trials comparing semaglutide against seven other diabetes medications across more than one million eligible patients and found semaglutide was associated with a 40-70% lower risk of a first-time Alzheimer’s diagnosis, with the strongest effect (67% lower risk) compared with insulin, published in Alzheimer’s & Dementia (2024) and a related follow-up study (2025).

How do you hold a failed treatment trial and a strong prevention signal together? The honest reading is that these measure different things: EVOKE tested whether semaglutide can slow disease that has already taken hold; the real-world studies suggest it may lower the odds of the disease developing in the first place, plausibly through years of better metabolic and vascular health rather than any direct action on the brain. Real-world data of this kind is also more prone to hidden bias — people who stay on a diabetes medication for years are systematically different from those who don’t, in ways researchers can adjust for but never fully eliminate. Neither the failure nor the signal should be discarded; both should be reported, which is more than most coverage of either result did on its own.

The Muscle Loss Problem

This is the risk longevity-minded users are best positioned to actually appreciate — and the one most likely to be glossed over in a clinic sales conversation.

Across clinical trials, GLP-1-driven weight loss doesn’t come only from fat. A 2024 review in Diabetes, Obesity and Metabolism by researcher Ian Neeland and colleagues found that tirzepatide (15mg) and semaglutide (2.4mg) — the most effective doses for fat loss — were also among the least effective at preserving lean mass, with lean tissue accounting for roughly 25-40% of total weight lost across recent trials. For comparison, diet-only weight loss typically runs closer to 20-25% lean mass. A 2026 real-world “digital phenotyping” analysis found tirzepatide caused measurably greater lean-mass decline than semaglutide, plausibly linked to its broader receptor activity.

For someone with obesity losing 60+ pounds, some muscle loss alongside a large fat loss is a reasonable trade. For a lean, already-fit person taking a microdose specifically to preserve healthspan, losing muscle — the tissue most strongly linked to healthy aging, fall prevention, and metabolic reserve in older adults — is close to the opposite of the intended effect, and it’s rarely mentioned in clinic marketing that leads with terms like “cellular health” and “inflammation.”

The only mitigation strategies with real study support are unglamorous: structured resistance training three to five days a week, and higher protein intake (studies of people who preserved lean mass on these drugs used roughly 0.7-1.7 g of protein per kilogram of body weight per day). A newer generation of “muscle-sparing” combination drugs — most notably bimagrumab paired with semaglutide — showed encouraging Phase 2 results and are now in Phase 3 trials, but none are approved or available as of 2026.

What Happens When You Stop

Nobody selling a GLP-1 longevity program tends to lead with this, but it’s some of the most consequential data in the entire evidence base for anyone weighing a long-term commitment.

In the STEP 4 trial, participants first lost an average of 10.6% of their body weight over 20 weeks on semaglutide, then were randomized to continue the drug or switch to placebo. Over the following year, the placebo group regained 6.9% of their original baseline weight — roughly two-thirds of what they had lost — while the group that continued treatment lost an additional 7.9%. In SURMOUNT-4, participants lost an average of 20.9% of body weight over 36 weeks on tirzepatide before randomization; the placebo group regained 14% of baseline weight within a year, more than half their total loss, while the continuing group lost a further 5.5%.

Critically, the regain isn’t just cosmetic — trials consistently show the blood pressure, blood sugar, and lipid improvements achieved on the drug reverse in step with the weight regain after stopping. This turns the practical decision into something closer to starting a blood pressure medication than taking a course of antibiotics: for the population these drugs are approved for, the benefit appears to require staying on the drug indefinitely, which has real implications for cost, side-effect exposure, and the muscle-loss dynamics above, compounding over years rather than months.

Safety: What’s Resolved, What Remains, and What’s Genuinely Unknown

The suicidal ideation scare has largely been resolved — in the drug’s favor. Following postmarketing reports that began in July 2023, the FDA conducted a comprehensive review, including a meta-analysis spanning 91 placebo-controlled trials and 107,910 patients across GLP-1 drug development programs. In a Drug Safety Communication issued January 13, 2026, the FDA concluded the data “did not demonstrate an increased risk” of suicidal thoughts, behavior, or related psychiatric events, and formally requested that manufacturers remove that warning language from drug labeling. This is a genuine example of the regulatory process working as intended — a real signal was investigated rigorously and, on the evidence, walked back.

The thyroid warning remains, and it’s more nuanced than “GLP-1 drugs cause thyroid cancer.” A boxed warning still applies against use in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), based on studies showing these drugs cause thyroid C-cell tumors in rodents. The available human evidence has not shown that GLP-1 drugs cause the far more common types of thyroid cancer or worsen existing thyroid malignancies — but the rodent signal is real enough that the warning, and the screening question about personal/family MTC or MEN2 history, isn’t precautionary theater.

Cancer risk overall looks reassuring, with one caveat worth watching. A large 2025 target trial emulation study using electronic health records from the OneFlorida+ network (43,317 GLP-1 users matched against 43,315 non-users) found an overall reduction in obesity-related cancer risk (hazard ratio 0.83), with statistically significant reductions in endometrial cancer, ovarian cancer, meningioma, and esophageal adenocarcinoma. The same analysis found a trend toward higher kidney cancer risk (hazard ratio 1.38) that didn’t reach statistical significance but is flagged for continued surveillance, particularly in younger and overweight (rather than obese) patients. As with the Alzheimer’s data, this is observational evidence, not a randomized trial, and carries the same caveats about who tends to stay on these medications long enough to be studied.

The honest gap: nobody has 20-40 years of data. Every trial cited in this article — SELECT, FLOW, STEP 4, SURMOUNT-4, the FDA’s safety reviews — covers one to roughly five years of exposure. “Longevity dosing,” by definition, implies decades of continuous use starting in a person’s 30s, 40s, or 50s. No dataset like that exists yet for any GLP-1 drug, for the simple reason that the drug class hasn’t been in wide use long enough to generate one. This isn’t a reason to assume long-term use is dangerous — it’s a reason to be precise about the difference between “well-studied for 1-5 years in people with disease” and “well-studied for the multi-decade horizon the longevity framing implies.”

The Compounded-Drug Problem

During the 2022-2024 supply shortages of brand-name semaglutide and tirzepatide, compounding pharmacies stepped in with lower-cost, non-brand versions, and a large share of the “GLP-1 for longevity” telehealth industry was built on that supply. That legal and safety landscape has shifted sharply. The tirzepatide shortage was declared resolved in December 2024 and the semaglutide shortage in February 2025 — which removed the FDA’s legal justification for large-scale compounding of these specific drugs. Since then, the FDA has issued more than 50 warning letters to U.S. and international compounders and manufacturers (September 2025), logged more than 1,700 adverse event reports tied to compounded semaglutide and tirzepatide — including hospitalizations from dosing errors when patients self-administered incorrect amounts from multidose vials — and proposed excluding semaglutide, tirzepatide, and liraglutide from the list of substances outsourcing facilities can legally compound in bulk, with a public comment period running through June 2026.

None of this means every compounded product is dangerous or fraudulent. It does mean the regulatory ground underneath the cheaper, non-brand version of this drug is actively shifting toward closure, and some products on that market have carried false pharmacy labeling. Anyone considering a compounded product in 2026 should treat “it’s cheaper” as a decision that now comes with materially more regulatory and quality uncertainty than it did in 2023.

The Cosmetic Trade-Off: “Ozempic Face”

Dermatologists have documented a consistent pattern — facial hollowing under the eyes, reduced cheek volume, jowling, and skin laxity — that tracks with rapid, significant weight loss on GLP-1 drugs, formalized in the dermatology literature as “Ozempic face.” The current evidence, including a 2024 review in Dermatological Reviews by researcher A. Montecinos and colleagues, attributes this primarily to fat volume loss outpacing the skin’s ability to recoil, rather than a direct toxic effect of the drug on skin tissue — the same phenomenon happens after major weight loss from any cause, including bariatric surgery. It’s meaningfully more pronounced in people over 40, whose baseline collagen and elastin reserves are already declining, which is a relevant consideration for the demographic most likely to be sold “longevity dosing” in the first place.

The Psychology of the Longevity Pitch

This pattern will be familiar to anyone who’s read ScanGlean’s coverage of rapamycin or peptide therapy: a drug with genuinely strong evidence in a specific, sicker population gets marketed to a healthier, younger population on the strength of a plausible mechanism and a handful of observational studies, well ahead of any trial actually testing that specific use.

Borrowed authority. SELECT and FLOW are real, rigorous, landmark trials — and clinics selling microdoses to healthy people are, whether they say so explicitly or not, borrowing the authority of those trials for a use case those trials didn’t test. The tell is in the language: “clinically proven” or “backed by major trials” is true of GLP-1 drugs in general and false of low-dose, indefinite use in healthy people specifically.

The mechanism-as-proof trap. “It reduces inflammation” and “it has anti-aging effects in mice” are real findings from mechanistic and animal research, and they’re also exactly the kind of finding that’s historically preceded both genuine breakthroughs (statins, metformin) and expensive dead ends (dozens of once-promising anti-aging compounds) in human trials. A plausible mechanism is a reason to fund a trial, not a reason to conclude the trial’s result in advance.

Self-selection in the enthusiasm. People who feel great on a GLP-1 microdose are disproportionately likely to post about it; people who develop nausea, lose visible muscle tone, or simply feel nothing different are far less likely to generate content. The online conversation around “GLP-1 longevity dosing” is not a representative sample of outcomes.

Where This Fits in the Longevity Clinic Landscape

GLP-1 programs have become a common add-on at both dedicated telehealth weight-loss companies and full-service longevity clinics, priced very differently depending on the format. Standalone GLP-1 telehealth programs commonly start around $179-$300 per month for the medication and physician oversight. At comprehensive longevity clinics — the kind we compare in our U.S. longevity clinic guide — GLP-1 prescribing is typically bundled into broader annual memberships that range from roughly $10,000 to well over $100,000, alongside bloodwork, imaging, and physician consultations, which makes the marginal cost of the GLP-1 component hard to isolate from the rest of the program.

As with TRT clinics, the presence of a real, evidence-backed drug at a clinic doesn’t automatically validate every use of it the clinic sells. The distinction that matters is the one this article has tried to hold onto throughout: strong evidence exists for specific populations and specific doses; the extension to healthy, normal-weight people at fractional doses for indefinite anti-aging purposes is a real hypothesis, being sold ahead of the data that would confirm or refute it.

So, Should You Consider GLP-1 Therapy?

For people with obesity, type 2 diabetes, or existing cardiovascular or kidney disease, the case is straightforward and well-supported: these drugs have randomized trial evidence for meaningful, hard-outcome benefits, and that evidence should factor heavily into a conversation with your physician.

For healthy, normal-weight people specifically pursuing “longevity microdosing”: you would be acting on a plausible but unproven hypothesis, using a drug with real, documented side effects (including muscle loss that runs counter to your own goals), a rebound effect if you ever stop, and no long-term human data at the dose and duration you’d actually be using. That’s not automatically the wrong choice for every individual — some people make informed bets on unproven-but-plausible interventions — but it should be made with that framing, not with the framing that a cardiovascular outcomes trial in sick patients has already settled the question for you.

The Bottom Line

GLP-1 drugs carry two genuinely different evidence profiles depending on who’s using them. In people with obesity, diabetes, or existing cardiovascular or kidney disease, the trial evidence — SELECT, FLOW, and the drugs’ original approval trials — is about as strong as preventive medicine gets. In healthy, normal-weight people using fractional “microdoses” indefinitely for anti-aging purposes, the evidence is, honestly, not there yet: no completed randomized trial has tested that specific protocol, muscle loss is a real and probably underweighted cost, stopping the drug reverses most of its benefit within a year, and nobody has the decades of data the “longevity” framing implicitly promises.

None of that makes these drugs a scam or the clinics selling them dishonest by definition. It means the honest way to evaluate a GLP-1 longevity offer is to ask which population the evidence you’re being shown actually came from — and to notice, clearly, when the answer is “not people like me.”

Curious which preventive interventions are actually backed by evidence for your situation? Answer a few quick, non-identifying questions and get personalized eligibility guidance across all 6 categories ScanGlean covers. Take the Fit Check →

Frequently Asked Questions

What are GLP-1 drugs, and why are longevity clinics offering them to people who aren’t diabetic or obese?

GLP-1 receptor agonists (semaglutide, tirzepatide, and related drugs sold as Ozempic, Wegovy, Mounjaro, and Zepbound) were developed for type 2 diabetes and later approved for obesity. Longevity clinics now offer them to lean, metabolically healthy people because large trials have shown benefits beyond weight loss — including reduced cardiovascular events and slower kidney disease progression — that appeared even in some patients without diabetes. Clinics market this as a broader “metabolic longevity” effect, though the strongest evidence comes from people who started with obesity, diabetes, or existing cardiovascular disease, not from healthy people at a normal weight.

Is there real clinical trial evidence that GLP-1 drugs extend lifespan, not just treat obesity or diabetes?

There’s strong randomized trial evidence for specific health outcomes in specific populations — not for lifespan extension in healthy people. The 2023 SELECT trial (17,604 people with overweight/obesity and existing cardiovascular disease, but not diabetes) found semaglutide reduced cardiovascular death, heart attack, or stroke by 20% over roughly 40 months. The 2024 FLOW trial found semaglutide slowed kidney disease progression by 21% in people with type 2 diabetes and chronic kidney disease. No randomized trial has tested whether GLP-1 drugs extend lifespan in healthy, normal-weight adults, which is the population much of the “longevity dosing” marketing targets.

What is “GLP-1 microdosing” for longevity, and does the evidence support it?

Microdosing means staying at roughly 25-50% of the standard maintenance dose long-term, typically in people who are not significantly overweight, with the stated goal of anti-inflammatory or “healthy aging” effects rather than weight loss. There is no FDA-approved microdose indication for any GLP-1 drug, and as of 2026 there is no published randomized controlled trial evidence supporting it — a bariatric medicine specialist at the University of Missouri put it bluntly: “there is no rigorous scientific data to support microdosing.” A prospective cohort study (AgelessRx, ClinicalTrials.gov NCT07092605) is currently underway to evaluate it, but results aren’t yet available.

Do GLP-1 drugs cause muscle loss, and how much?

Yes, measurably. Across clinical trials, roughly 25-40% of the total weight lost on GLP-1 drugs is lean mass (muscle, not just fat) rather than the roughly 20-25% lean-mass share typical of diet-only weight loss. A 2024 review in Diabetes, Obesity and Metabolism by Neeland and colleagues found tirzepatide and semaglutide were most effective for fat loss but among the least effective at preserving lean mass, and a 2026 real-world digital phenotyping study found tirzepatide causes greater lean mass decline than semaglutide. Resistance training and adequate protein intake (roughly 0.7-1.7 g/kg/day in studies of people who preserved lean mass) are the primary mitigation strategies studied so far.

What happens if you stop taking a GLP-1 drug — do you regain the weight?

Most of it, and relatively quickly. In the STEP 4 trial, people who lost 10.6% of their body weight on semaglutide and then switched to placebo regained 6.9% of their baseline weight within a year — about two-thirds of what they’d lost — while those who continued treatment lost further weight. In SURMOUNT-4, people who lost 20.9% of body weight on tirzepatide and then switched to placebo regained 14% of baseline weight, more than half of their total loss, within a year. Weight regain after stopping is consistently accompanied by reversal of the blood pressure, blood sugar, and other metabolic improvements the drug produced.

Are GLP-1 drugs safe for healthy, non-diabetic people to use long-term?

The most common side effects (nausea, vomiting, diarrhea, constipation) are well documented and usually manageable. On the safety questions that concerned people most, the picture has shifted: in January 2026, the FDA requested removal of the suicidal-ideation warning after a review of 91 placebo-controlled trials covering 107,910 patients found no increased psychiatric risk. A boxed warning against use in people with a personal or family history of medullary thyroid carcinoma or MEN2 remains, based on rodent tumor data that hasn’t been confirmed in humans for common thyroid cancers. What’s genuinely unstudied is safety over the 20-40 years a healthy person considering “longevity dosing” might realistically stay on the drug — the trials informing today’s safety profile run for one to five years.

What’s “Ozempic face,” and why does it happen?

It’s a colloquial term for facial changes — hollowing under the eyes, cheek volume loss, jowling, and skin laxity — that can accompany rapid, significant weight loss from any cause, including GLP-1 drugs. Current dermatological evidence attributes it mainly to fat volume loss and the speed of weight loss outpacing skin’s ability to recoil, rather than a direct effect of the drug on skin itself. It’s more pronounced in people over 40, whose baseline collagen and skin elasticity are already reduced — a 32-year-old losing 40 pounds on semaglutide may show minimal facial change, while a 52-year-old losing the same amount often shows more.

How much does GLP-1 therapy cost at a longevity clinic, and is compounded semaglutide or tirzepatide safe to use instead?

Branded GLP-1 drugs through telehealth or concierge longevity programs commonly start around $179-$300 per month before insurance, on top of clinic membership fees that range from roughly $10,000 to $150,000+ per year at full-service longevity clinics. Compounded (non-brand-name) versions became widely available during 2022-2024 shortages of the brand-name drugs, but both shortages have since resolved, and the FDA has issued more than 50 warning letters to compounders since September 2025, logged over 1,700 adverse event reports tied to compounded semaglutide and tirzepatide (including dosing errors from multidose vials), and proposed excluding these drugs from the list of substances legally compoundable in bulk — a strong signal that the compounded-drug pathway is closing.

This article is for general educational and informational purposes only. It is not medical advice, and it is not a substitute for diagnosis, treatment, or guidance from a licensed physician or other qualified healthcare provider. GLP-1 receptor agonists are prescription medications with real risks and contraindications, including a boxed warning for personal or family history of medullary thyroid carcinoma or MEN2. Anyone considering these drugs, for any purpose, should do so under the supervision of a licensed physician.

Sources

← Back to all guides

Newsletter

Before you go — get new comparisons first.

One email when we publish a new provider comparison, cost guide, or evidence review. No spam, no clinic promotions.